2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a [b] c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1913

B Cell Depletion Therapy Impact CD8 T Cells in ANCA-Associated Vasculitis
Abstract Number: 2117

B Cell Phenotype and in Vitro Function in Patients with Rheumatoid Arthritis Developing Low Serum Immunoglobulins after Multiple Cycles of Rituximab
Abstract Number: 917

B Cells Inhibit Osteoblast Differentiation in Inflammatory Arthritis
Abstract Number: 2873

B-Cell activating Factor Genetic Variants in Systemic Lupus Erythematosus and Lupus Related Atherosclerosis
Abstract Number: 1080

B-Cell Clonal Expansions in Parotid Glands of Sjogren’s Patients Are Associated with Increased Numbers of N-Glycosylation Motifs in the Immunoglobulin Heavy Chain Genes
Abstract Number: 2772

Back Pain in Psoriatic Arthritis: Defining Prevalence, Characteristics and Performance of the Different Inflammatory Back Pain Criteria in a Psoriatic Arthritis Cohort
Abstract Number: 1417

Back to Feeling Normal Again: Patients with Rheumatoid Arthritis in Remission
Abstract Number: 2710

Bacterial Dysbiosis Associates with Functional Intraepithelial Lymphocyte Changes in Inflammatory Bowel Disease and Spondyloarthritis
Abstract Number: 1076

BAFF Receptor Antagonists Suppress Differentiation of B Cells in Vitro and Are Drug Candidates for Primary SjöGren’s Syndrome
Abstract Number: 844

Bardoxolone Methyl Produces Durable Benefits in Participants with Pulmonary Arterial Hypertension: Data from an Open-Label Extension Study
Abstract Number: 1584

Bari-00074565
Abstract Number: 1593

Baricitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Abstract Number: 2959

Baseline Endothelial Dysfunction Might Predict Immunosuppressive Need in Young, Male Behcet’s Patients with Early Disease: A Prospective Follow-up
Abstract Number: 1702

Baseline Patient Characteristics Associated with Response to Biologic Therapy in Patients with Psoriatic Arthritis Enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Abstract Number: 28

Baseline Serum Inflammatory Biomarkers at Cohort Entry in 1974 Predicted Cardiovascular Disease (CVD) Mortality from 1995 through 2015 in a Prospective, Community-Based Study of Incident Rheumatoid Arthritis (RA) Patients and Matched Non-RA (CN) Subjects
Abstract Number: 1652

Basement Membrane Remodeling Is Significantly Increased with Rheumatoid Arthritis and Suppressed By IL6 Inhibition: Analysis of Two Phase III Clinical Trial
Abstract Number: 811

Basophils Are Activated and Stimulate Both B Cells and Fibroblasts in Systemic Sclerosis
Abstract Number: 2940

Bechet’s Disease and Sleep Quality in Korean Patients
Abstract Number: 508

Before Clinically Detectable Arthritis Develops, ACPA-Positive and ACPA-Negative Arthralgia Patients Have Different Symptoms
Abstract Number: 2963

BehçEt’s Disease in Children: Eastern Mediterranean Experience
Abstract Number: 780

Belimumab Use in African-American Patients in an U.S. Academic Medical Center
Abstract Number: 1681

Beneficial Effect of n-3 Polyunsaturated Fatty Acids on Inflammation and Analgesic Use in Psoriatic Arthritis – a Randomised, Double Blind, Placebo-Controlled Trial
Abstract Number: 12

Benefit of Early Therapy with Methotrexate and Prednisone in Patients with Early Rheumatoid Arthritis and Undifferentiated Early Arthritis (CONAART)
Abstract Number: 2779

Better Health-Related Quality of Life and Work Capacity in Patients Achieving Inactive Disease and Clinical Response in Patients with Non-Radiographic Axial Spondyloarthritis
Abstract Number: 1005

Biallelic Hypomorphic Mutations in a Linear Deubiquitinase Define Otulipenia, an Early-Onset Systemic Autoinflammatory Disease
Abstract Number: 2013

BIIB059, a Monoclonal Antibody Targeting BDCA2, Shows Evidence of Biological Activity and Early Clinical Proof of Concept in Subjects with Active Cutaneous SLE
Abstract Number: 774

BIIB059, an Anti-BDCA2 Monoclonal Antibody, Demonstrates Acceptable Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamic (PD) Effects in a Phase 1 Study with Single Ascending Doses (SAD) in Healthy Volunteers
Abstract Number: 2060

Bim Suppresses the Development of SLE By Limiting Macrophage Inflammatory Responses
Abstract Number: 2994

Binding of Periostin to Discoidin Domain Receptor-1 (DDR1) Promotes Cartilage Degeneration By Inducing MMP-13 Expression
Abstract Number: 331

Biologic Disease-Modifying Anti-Rheumatic Drug Use and the Risk of Non-Vertebral Osteoporotic Fractures in Japanese Patients with Rheumatoid Arthritis: Results from the IORRA Cohort Study
Abstract Number: 2237

Biologic DMARD Use Among U.S. Patients in an Online Rheumatoid Arthritis Community
Abstract Number: 631

Biologic Free Remission Rate with Etanercept in Rheumatoid Arthritis: A Potential Role of Gender
Abstract Number: 637

Biologic Initiation Patterns Among Rheumatoid Arthritis Patients in Moderate or High Disease Activity While Using Conventional Disease Modifying Anti-Rheumatic Drugs
Abstract Number: 2955

Biologic Therapy in Severe Peripheral Ulcerative Keratitis (PUK). Multicenter Study of 27 Patients
Abstract Number: 2375

Biologic Therapy Modifies Clinical and Laboratory Features of Macrophage Activation Syndrome Associated with Systemic Juvenile Idiopathic Arthritis
Abstract Number: 2669

Biological Treatments in Primary SjöGren Syndrome
Abstract Number: 799

Biomarker Identification & Molecular Sub-Classification in Systemic Sclerosis for Precision Medicine Using RNA-Seq
Abstract Number: 1492

Biomarker-Related Risk for Myocardial Infarction and Serious Infections in Patients with Rheumatoid Arthritis: A Population-Based Study
Abstract Number: 2286

Bioresponsive Glucocorticoid-Loaded Microparticles to Prevent Acute Gout Flares
Abstract Number: 19L

Biosimilar Infliximab (CT-P13) Is Not Inferior to Originator Infliximab: Results from a 52-Week Randomized Switch Trial in Norway
Abstract Number: 2436

Birth Outcomes Significantly Worsen after the Development of Systemic Lupus Erythematosus in a Population-Based Registry
Abstract Number: 348

Bisphosphonates-Related Atypical Femur Fractures: 8 Years’ Experience in a Single Center
Abstract Number: 2064

Blood and Kidney Molecular Profiles Distinguish Subjects with Lupus Nephritis from Other Kidney Disorders
Abstract Number: 11L

BMS-986165 Is a Highly Potent and Selective Allosteric Inhibitor of Tyk2, Blocks IL-12, IL-23 and Type I Interferon Signaling and Provides for Robust Efficacy in Preclinical Models of Systemic Lupus Erythematosus and Inflammatory Bowel Disease
Abstract Number: 3204

Body Composition and Adipose Tissue Distribution in Juvenile Dermatomyositis and Associations with Cardiac Function
Abstract Number: 1583

Body Mass Index Does Not Affect Response to Subcutaneous or Intravenous Abatacept in Patients with Rheumatoid Arthritis
Abstract Number: 1589

Body Mass Index Does Not Impact Abatacept Retention in Biologic-Naive Patients with Rheumatoid Arthritis Who Have Poor Prognostic Factors: A 12-Month Interim Analysis of an Observational, Prospective Study
Abstract Number: 548

Body Mass Index Is Positively Correlated with Diverse Disease Activity Measures in Longstanding Rheumatoid Arthritis
Abstract Number: 1105

Bone Metabolism in Rheumatic Diseases May be Affected By Free Fatty Acids
Abstract Number: 167

Bone Mineral Density Loss in Clinically Suspect Arthralgia Is Associated with Subclinical Inflammation and Progression to Clinical Arthritis
Abstract Number: 3229

Bone Morphogenetic Protein 6 Receptor Inhibition Restores Salivary Gland Function in a Mouse Model of Primary Sjögren’s Syndrome
Abstract Number: 2134

Bone Replaces Cartilage in Non-Weight Bearing Regions of Immobilized Knees
Abstract Number: 1512

Bone Structural Deficits in Rheumatoid Arthritis: Impact of Muscle Mass and Density
Abstract Number: 546

Boolean-Based Remission in Rheumatoid Arthritis Using Physician Versus Patient Global Assessment: Differences in Ultrasonographic Disease Activities, Sustainabilities, and Relapse Rates
Abstract Number: 2787

Bortezomib Treatment Induces Higher Mortality Rate in Lupus Model Mice with High Disease Activity
Abstract Number: 2782

Bortezomib Treatment Prevents Glomerulosclerosis Associated with Lupus Nephritis in a Murine Model through Suppressive Effects on the Immune and Renin-Angiotensin Systems
Abstract Number: 998

Brain Responses to Other’s Pain in Fibromyalgia – a Magnetoencephalography (MEG) Study
Abstract Number: 3139

Breaking the Cycle: Analyzing Preventable Hospital Admissions Due to Gout
Abstract Number: 2816

Broad Autoantibody Profiling in Ethnically Diverse SLE Cohorts Reveals a Set of Conserved Autoantibodies That Are Correlated to a Type I Interferon Signature
Abstract Number: 3217

Broad-Based Interrogation of the Serum Proteome Suggests That RA Onset Is Associated with Activation of the Intrinsic Coagulation Cascade
Abstract Number: 1938

Bronchiectasis Are Highly Prevalent in Anti-MPO ANCA-Associated Vasculitis and Associate with a Distinct Disease Phenotype

Jump to: View All • a [b] c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].